Ryan Schwarz Managing Director
Mr. Schwarz has 20 years of investment and financial experience in healthcare. For fourteen years from 1997 to 2011, Mr. Schwarz led the US healthcare growth capital practice at The Carlyle Group. His team’s investing activities focused on healthcare services, digital health and medical products. He joined The Carlyle Group at the inception of its initial US venture and growth capital fund in 1997, and led the healthcare investing practice through all three of the firm’s domestic growth capital funds, which targeted growth and venture capital investments and growth-oriented leveraged buyouts.
Mr. Schwarz previously was a Vice President in the healthcare group at Robertson Stephens, where he led the firm’s digital health investment banking efforts and also served clients in the healthcare services sector. Earlier in his career, Mr. Schwarz was an investment banker at Morgan Stanley.
Mr. Schwarz is currently the Chairman of the Board of Directors of Lucent Health Solutions and of OPN Healthcare. He also serves as a member of the Board of Directors of Proteus Digital Health. He was formerly a Director of numerous prior portfolio companies of The Carlyle Group, including AqueSys (sold o Allergan), Carefx (sold to Harris Corporation), ConnectiCare Holdings (sold to EmblemHealth), Endius (sold to Zimmer), Fairchild Imaging (sold to BAE Systems), LipoSonix (sold to Medicis Pharmaceuticals) and Heritage Health Systems (sold to Universal American Financial).
In the non-profit sector, Mr. Schwarz serves as President of the Hungarian-American Enterprise Scholarship Fund, which provides fellowships to promising young Hungarian nationals to obtain private sector professional experience in the United States.
Mr. Schwarz holds an AB from Duke University where he was an Angier B. Duke Scholar, an MBA from Harvard Business School, and a JD from Harvard Law School.